The dream was straight out of a 1970s sci-fi flick. You take a person who has been living in total darkness for decades, strap a pair of high-tech glasses on them, and suddenly, they can see again. It wasn't just a movie plot. For a while, Second Sight Medical Products actually made it happen. They were the darlings of the med-tech world, the pioneers of the "bionic eye." But if you follow medical news at all, you know that the story didn't end with a triumphant sunset. It ended with a lot of confused patients and some very complex corporate maneuvering.
Honestly, the technology was staggering.
We’re talking about the Argus II Retinal Prosthesis System. It was the first of its kind to get FDA approval. Basically, it worked by bypassing damaged photoreceptor cells in people with Retinitis Pigmentosa (RP). A tiny camera on the patient's glasses sent data to a video processing unit, which then beamed signals to an electrode array implanted directly on the retina. It didn't provide "natural" vision—nobody was seeing 4K resolution—but it gave people back the ability to see light, shapes, and movement. For someone who hasn't seen their spouse's silhouette in twenty years, that's everything.
The Rise and Sudden Stall of Argus II
The Argus II was a marvel, but it was also incredibly expensive. We’re talking $150,000 or more just for the hardware, not even counting the surgery. Despite the price tag, more than 350 people worldwide had these systems implanted. They became part of a small, elite group of "cyborgs" who relied on Second Sight Medical Products to maintain the software and hardware that governed their sight.
Then, things got weird.
Around 2019 and 2020, the company started hitting major financial speedbumps. They stopped making the Argus II. They laid off most of their staff. Suddenly, those 350 patients were left with "orphan technology." If your glasses broke or the internal software glitched, there was basically nobody left to pick up the phone. It's a terrifying thought. Imagine having a piece of high-tech hardware literally sewn into your eye, and the company that holds the "keys" to it just... vanishes.
The Orion Project and the Pivot to the Brain
Second Sight didn't just want to fix the retina. They realized that many people are blind for reasons that have nothing to do with the eye itself—like glaucoma or trauma to the optic nerve. Their next big swing was Orion.
Orion was even more ambitious than Argus. Instead of an implant on the retina, Orion was a cortical stimulator. It bypassed the eyes entirely and plugged straight into the visual cortex of the brain. The logic was simple: if the "wires" from the eye to the brain are broken, just talk to the brain directly.
Early trials were actually quite promising.
- Six participants at UCLA and Baylor College of Medicine were part of the feasibility study.
- The system used the same camera-to-glasses setup as the Argus.
- Initial results showed that even patients who had been blind for years could perceive spots of light called phosphenes.
But the corporate instability made the Orion project feel like a house of cards. When the company nearly collapsed in 2020, the future of brain-implanted vision looked grim.
The Vivani Merger: A Change of Direction
In 2022, the saga took another turn. Second Sight Medical Products merged with a company called Nano Precision Medical, eventually becoming Vivani Medical. Now, if you look at Vivani today, they aren't talking much about bionic eyes. Their primary focus has shifted toward long-term drug delivery systems, specifically for chronic diseases like diabetes and obesity.
It’s a classic business pivot.
📖 Related: macbook os high sierra: Why This Ancient Software Still Refuses to Die
Building bionic eyes is incredibly hard and notoriously difficult to make profitable. Delivering GLP-1 medications via a tiny, subdermal implant? That’s where the market is moving. But where does that leave the vision tech?
Well, the intellectual property for the Argus and Orion systems didn't just disappear. There have been ongoing discussions about how to support the existing patient base, but for many, the damage was done. The "Second Sight" brand became a cautionary tale in the medical ethics community about what happens when life-altering technology is tied to the volatility of a venture-backed startup.
Why Scaling Bionic Vision Is So Hard
You might wonder why we don't have these eyes everywhere by 2026. The tech is there, right? Sorta. But there are three massive hurdles that Second Sight Medical Products struggled to clear:
- Resolution Limits: The Argus II had 60 electrodes. That’s like trying to see the world through a 60-pixel screen. You can see a doorway, but you can't read a book.
- Surgical Complexity: These aren't simple procedures. Putting an electrode array on a delicate, thinning retina or drilling into the skull for a cortical implant carries massive risks like infection or device migration.
- Regulatory & Reimbursement Nightmares: Getting insurance companies to pay $150k for "partial" vision is a tough sell. Without widespread insurance coverage, the market stays tiny, and the company can't sustain the R&D costs.
What Most People Get Wrong About the Technology
People often think "bionic eye" means a camera that works just like a human eye. It doesn't.
When you use a product like the ones developed by Second Sight, your brain has to learn a completely new language. Patients often described it as seeing flashes of light or "stars." They had to undergo months of "vision rehab" to train their brains to interpret those flashes as a curb, a person, or a plate on a table. It’s an exhausting mental process. It’s not like putting on a pair of prescription glasses and everything clicking into focus. It’s more like learning to see via a very low-resolution, flickering radar.
The Future: Pixium Vision and Science Corp
Even though the Second Sight we knew has transformed into a drug-delivery company, the mission isn't dead. Other players have stepped into the vacuum.
Pixium Vision, a French company, has been working on the Prima System. It’s a subretinal implant that’s much smaller and potentially offers better resolution for people with dry Age-Related Macular Degeneration (AMD). Then there’s Science Corp, founded by Max Hodak (formerly of Neuralink). They acquired the IP and assets related to the Argus and Orion tech.
This is actually a huge deal.
Science Corp is working on something they call the "Science Eye." They are trying to combine gene therapy with a high-resolution micro-LED display placed on the retina. By using the Second Sight heritage as a foundation, they might actually solve the support issues that left those 350 patients in the lurch. It’s a bit of a "phoenix rising" situation for the technology.
Real-World Actionable Insights for Patients and Investors
If you or a loved one are looking into vision restoration technology, or if you’re an investor eyeing the med-tech space, here is the ground truth.
- Clinical Trials are the Gateway: Don't wait for a commercial product. The most advanced vision tech is currently in the trial phase. Keep an eye on ClinicalTrials.gov for terms like "visual prosthesis" or "cortical stimulator."
- The "Orphan" Risk is Real: Before committing to any permanent implant, ask the tough questions about long-term support. What happens if the company is acquired? Is the software open-source or proprietary?
- Check the Science Eye: If you were following Second Sight Medical Products for their Orion brain implant, follow Science Corp now. They are the ones currently holding the mantle for that specific lineage of hardware.
- Manage Expectations: We are still years away from "The Six Million Dollar Man" levels of vision. Current tech is about mobility and independence—detecting a crosswalk or finding a doorway—not reading fine print or driving a car.
The story of Second Sight is a bit of a heartbreaker, but it’s also a necessary chapter in the history of human augmentation. We learned that the brain is willing to talk to our machines; we just haven't quite figured out how to keep the "telephone companies" in business long enough to finish the conversation.
The move toward Vivani Medical and the acquisition of the vision assets by Science Corp suggests that while the company name changed, the dream of restoring sight is just moving into a more stable, albeit different, phase of development. If you're looking for the next big leap, watch the intersection of optogenetics and micro-electronics. That's where the next "second sight" will likely come from.
To stay informed, look into the current feasibility studies for the Prima implant or the Science Eye project. These are the direct spiritual and technical successors to the Argus legacy. Keep your eyes on the startups that are prioritizing "repairability" and "long-term data stability," as these were the hard-learned lessons from the Argus II era.